

**Alzheimer's Association Business Consortium
AAIC In-person Meeting Summary
July 23, 2018, 12 – 1 p.m.
Hyatt Regency, Grant Park B Room**

Attendees:

| | |
|--------------------------------------|--|
| Kira Sheinerman, DiamiR- Co-chair | Ryan Smith, AiCure |
| Leen Kawas, M3Bio, Co-chair | Judy Walker, Accera |
| Jim Hendrix, Alzheimer's Association | John Didsbury, T3D Therapeutics |
| April Ross, Alzheimer's Association | Michael Goy, BrainBits |
| Justin Klee, Amylyx | Andreas Köpke, SynAging |
| Joshua Cohen, Amylyx | Joseph Araujo, InterVivo Solutions |
| Mike Vitek, Cognosci | Ambuj Singh, Acelot |
| Ian Sheriff, Araclon | Andy Satlin, Intra-Cellular Therapeutics |
| Mark Reed, Treventis | Josh Pan-M3Bio |
| Kevin Church, M3Bio | Suzanne Page, Longeveron |
| Anthony Oliva, Longeveron | |

- Webinar Feedback
 - Members had positive feedback regarding the webinars
 - **Action Item:** Jim to follow up with NIH regarding the scientific selection
 - Additional topic suggestions:
 - How to communicate failures/outcomes to raise funds/ how to present effective presentations and adapt to audiences.
 - Communication and Marketing
 - Invite a research analyst from a high investment research firm
 - How to assess blood based biomarkers, can invite someone from NIH
 - What's new in the neuroimaging and CSF space
 - Statistical models of clinical trials and outcome measures
- Members inquired about having access to the AAIC presenter posters and presentations.
- Communications Strategies/Collaborative Framework
 - Create a companies' chat forum – companies at specific funding stages, particular issues can discuss strategies/troubleshoot.
 - Social media-LinkedIn and Facebook
 - Host virtual break-out sessions with focused topics
 - **Action Item:** Members can email Jim and April what they are interested in.
- There is interest to have another F2F meeting at SfN. April will send a poll.
- This year elections will be held for the co-chair position to replace Kira.
- Members are encouraged to invite companies to the AABC the criteria for membership is that the company has an interest in research for Alzheimer's or dementia at any level.